Eikonoklastes Therapeutics to advance next-generation tissue factor (TF) immunotherapies

Platform technology targets tissue factor present in a broad range of cancers and other diseases with high unmet need; initial focus is triple-negative breast cancer; company closes oversubscribed seed financing is oversubscribed

Read more